
CLAIMS

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof;

wherein:

---- represents a single or double bond;

R^1 is substituted or unsubstituted C_{1-6} alkyl (e.g., haloalkyl, e.g., $-CHF_2$, $-CH_2F$, $-CH_2OCH_3$, $-CH_2OCH_2CH_3$), substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocyclyl;

R^2 is hydrogen, halogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocyclyl, or $-OR^{A2}$, wherein R^{A2} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocyclyl;

R^{3a} is hydrogen or $-OR^{A3}$, wherein R^{A3} is hydrogen or substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, or substituted or unsubstituted C_{3-6} carbocyclyl, and R^{3b} is hydrogen; or R^{3a} and R^{3b} are joined to form an oxo (=O) group;

each instance of R^{4a} and R^{4b} is independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, or halogen, provided if the ---- between C5 and C6 is a single bond, then the hydrogen at C5 and R^{4a} are each independently provided in the *alpha* or *beta* configuration, and R^{4b} is absent;

each instance of R^5, R^6, and R^7 is, independently, hydrogen, halogen, $-NO_2$, $-CN$, $-OR^{GA}$, $-N(R^{GA})_2$, $-C(=O)R^{GA}$, $-C(=O)OR^{GA}$, $-OC(=O)R^{GA}$, $-OC(=O)OR^{GA}$, $-C(=O)N(R^{GA})_2$, $-$


~~$N(R^{GA})C(=O)R^{GA}$, $-OC(=O)N(R^{GA})_2$, $-N(R^{GA})C(=O)OR^{GA}$, $-N(R^{GA})C(=O)N(R^{GA})_2$, $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, $-OS(=O)_2R^{GA}$, $-S(=O)_2N(R^{GA})_2$, $-N(R^{GA})S(=O)_2R^{GA}$, substituted or unsubstituted C_{1-6} alkyl (e.g., haloalkyl), substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, or substituted or unsubstituted 3- to 6- membered heterocylyl;~~

~~each instance of R^{GA} is independently hydrogen, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted C_{2-6} alkenyl, substituted or unsubstituted C_{2-6} alkynyl, substituted or unsubstituted C_{3-6} carbocylyl, substituted or unsubstituted 3- to 6- membered heterocylyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an oxygen protecting group when attached to oxygen, nitrogen protecting group when attached to nitrogen, or two R^{GA} groups are taken with the intervening atoms to form a substituted or unsubstituted heterocylyl or heteroaryl ring; and~~

~~wherein R^1 is C_{1-6} alkyl optionally substituted with alkoxy or one to two halo groups (e.g., fluoro), or wherein at least one of R^5, R^6, and R^7 is halogen (e.g., -F, -Cl, -Br), $-NO_2$, -CN, $-OR^{GA}$, $-N(R^{GA})_2$, $-C(=O)R^{GA}$, $-C(=O)OR^{GA}$, $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, $-OS(=O)_2R^{GA}$, $-S(=O)_2N(R^{GA})_2$, substituted or unsubstituted C_{1-6} alkyl (e.g., $-CH_3$, $-CH_2CH_3$, haloalkyl, e.g., $-CF_3$) , wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.~~


~~2. The compound of Formula (**I**) of claim 1, wherein R^1 is C_{1-6} alkyl optionally substituted with alkoxy or one to two halo groups (e.g., fluoro), and at least one of R^5, R^6, and R^7 is halogen (e.g., -F, -Cl, -Br), $-NO_2$, -CN, $-OR^{GA}$, $-N(R^{GA})_2$, $-C(=O)R^{GA}$, $-C(=O)OR^{GA}$, $-SR^{GA}$, $-S(O)R^{GA}$, *e.g.*, $S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, $-OS(=O)_2R^{GA}$, $-S(=O)_2N(R^{GA})_2$, substituted or unsubstituted C_{1-6} alkyl (e.g., $-CH_3$, $-CH_2CH_3$, haloalkyl, e.g., $-CF_3$) , wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.~~

~~3. The compound of Formula (**I**) of claim 1, wherein the compound is selected from a compound of Formula (**I-A**):~~



~~(I-A)~~

~~4. The compound of Formula (I) of claim 1, wherein the compound is selected from a compound of Formula (I-B):~~



~~(I-B)~~

~~5. The compound of claim 1, wherein R^1 is unsubstituted C_{1-6} alkyl.~~

~~6. The compound of claim 1, wherein R^1 is a C_{1-6} alkyl optionally substituted with alkoxy.~~

~~7. The compound of claim 1, wherein R^1 is a C_{1-6} alkyl optionally substituted with one or two halo (e.g., fluoro).~~

~~8. The compound of claim 1, wherein R^1 is $-CH_3$, $-CH_2CH_3$, $-CH_2F$, $-CHF_2$, $-CH_2OCH_2CH_3$, or $-CH_2OCH_3$.~~

~~9. The compound of claim 8, wherein R^1 is $-CH_3$.~~

10. The compound of claim 1, wherein R^2 is -OH, $-OCH_3$, $-OCH_2CH_3$, $-OCH_2CH_2CH_3$, $-CH_3$, $-CH_2CH_3$, $-CH_2CH_2CH_3$, substituted or unsubstituted cyclopropyl, fluoro, or chloro.

11. The compound of claim 10, wherein R^2 is $-CH_3$ or $-OCH_3$.

12. The compound of claim 11, wherein R^2 is $-OCH_3$.

13. The compound of claim 1, wherein R^2 is hydrogen.

14. The compound of claim 1, wherein R^{3a} and R^{3b} are both hydrogen.

15. The compound of claim 1, wherein ---- represents a single bond, and both of R^{4a} and R^{4b} are hydrogen.

16. The compound of claim 1, wherein ---- represents a single bond, and both of R^{4a} and R^{4b} are fluoro.

17. The compound of claim 1, wherein ---- represents a single bond, and R^{4a} is hydrogen, fluoro, $-CH_3$, or $-CF_3$.

18. The compound of claim 1, wherein ---- represents a single bond, and R^{4a} is substituted or unsubstituted C_{1-6} alkyl, or halogen, and R^{4b} is hydrogen.

19. The compound of claim 18, wherein R^{4a} is fluoro.

20. The compound of claim 1, wherein at least one of R^5, R^6, and R^7 is hydrogen.

21. The compound of claim 1, wherein at least two of R^5, R^6, and R^7 are hydrogen.

22. The compound of claim 1, wherein all of R^5, R^6, and R^7 are hydrogen.

23. The compound of claim 1, wherein at least one of R^5, R^6, and R^7 is substituted or unsubstituted C_{1-2} alkyl (e.g., $-CF_3$), $-CO_2R^{GA}$, $-C(=O)R^{GA}$, -CN, $-NO_2$, halogen, $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, or $-S(=O)_2N(R^{GA})_2$, wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.

24. The compound of claim 23, wherein at least one of R^5, R^6, and R^7 is -CN.

25. The compound of claim 23, wherein at least one of R^5, R^6, and R^7 is $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, or $-S(=O)_2N(R^{GA})_2$, wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.

26. The compound of claim 25, wherein at least one of R^5, R^6, and R^7 is $-S(=O)_2R^{GA}$.

27. The compound of claim 25, wherein R^{GA} is $-CH_3$.

28. The compound of claim 1, wherein R^5 and R^7 are hydrogen.

29. The compound of claim 1, wherein R^6 is halogen (e.g., -F, -Cl, -Br), $-NO_2$, -CN, $-OR^{GA}$, $-N(R^{GA})_2$, $-C(=O)R^{GA}$, $-C(=O)OR^{GA}$, $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, $-OS(=O)_2R^{GA}$, $-S(=O)_2N(R^{GA})_2$, substituted or unsubstituted C_{1-6} alkyl (e.g., $-CH_3$, $-CH_2CH_3$, haloalkyl, e.g., $-CF_3$), wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.

30. The compound of claim 29, wherein R^6 is $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, or $-S(=O)_2N(R^{GA})_2$, wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.

31. The compound of claim 29, wherein R^6 is halogen (e.g., -F, -Cl, -Br), $-NO_2$, -CN, or substituted or unsubstituted C_{1-6} alkyl (e.g., $-CH_3$, $-CH_2CH_3$, haloalkyl, e.g., $-CF_3$), wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.

32. The compound of claim 1, wherein R^2, R^{3a}, R^{3b}, R^{4a}, and R^{4b} are hydrogen.

33. The compound of claim 1, wherein at least three of R^2, R^{3a}, R^{3b}, R^{4a}, R^{4b}, R^5, R^6, and R^7 are hydrogen.

34. The compound of claim 1, wherein at least four of R^2, R^{3a}, R^{3b}, R^{4a}, R^{4b}, R^5, R^6, and R^7 are hydrogen.

35. The compound of claim 1, wherein at least five of R^2, R^{3a}, R^{3b}, R^{4a}, R^{4b}, R^5, R^6, and R^7 are hydrogen.


36. The compound of claim 35, wherein , R^6 is halogen (e.g., -F, -Cl, -Br), $-NO_2$, -CN, $-C(=O)R^{GA}$, $-C(=O)OR^{GA}$, $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, substituted or unsubstituted C_{1-6} alkyl (e.g., $-CH_3$, $-CH_2CH_3$, haloalkyl, e.g., $-CF_3$) , wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.















37. The compound of claim 36, wherein R^6 is $-SR^{GA}$, $-S(=O)R^{GA}$, $-S(=O)_2R^{GA}$, $-S(=O)_2OR^{GA}$, or $-S(=O)_2N(R^{GA})_2$, wherein R^{GA} is substituted or unsubstituted C_{1-2} alkyl.













38. The compound of claim 36, wherein R^6 is -CN.

39. The compound of claim 36, wherein R^1 is substituted or unsubstituted C_{1-6} alkyl (e.g., haloalkyl, e.g., $-CF_3$, $-CHF_2$, $-CH_2F$) or alkoxy.

40. The compound of claim 1, wherein the compound is selected from the group consisting of:


















5


~~41. The compound of claim 2, wherein the compound is selected from the group consisting of:~~




SA-1




SA-2




SA-3




SA-4




SA-5




SA-6




SA-7




SA-8




SA-9




SA-10




SA-11




SA-12




SA-13




SA-14




SA-15




SA-16




SA-17




SA-18




SA-20




SA-21




SA-22




SA-23




SA-24




SA-25




SA-27




SA-28




SA-29




SA-30 ;




SA-31 ;



SA-32 ;




SA-33 ~~, and~~




SA-35 .


~~42. The compound of claim 3, wherein the compound is selected from the group consisting of:~~




SB-1




SB-2




SB-3




SB-4




SB-5




SB-7




SB-8




SB-9




SB-10




SB-11 ,




SB-12 ,




SB-13 ,




SB-14 ,




SB-15 ,




SB-18 ,




SB-19 ,




SB-20 ,



SB-21 ,



SB-22 , and



SB-23 .

5

~~43. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of any one of the preceding claims, and a pharmaceutically acceptable excipient.~~


~~44. A method for treating a CNS-related disorder in a subject in need thereof, comprising administering to the subject an effective amount of a compound of any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof.~~

~~45. The method of claim 44, wherein the CNS-related disorder is a sleep disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.~~

~~46. The method of claim 44 wherein the compound is administered orally, subcutaneously, intravenously, or intramuscularly.~~


~~47. The method of claim 44 wherein the compound is administered chronically.~~

1. Use of a pharmaceutically acceptable salt of a compound of the formula:



in the manufacture of a medicament for treating a mood disorder in a human subject.

2. Use of a compound of the formula:



in the manufacture of a medicament for treating a mood disorder in a human subject.


3. The use of claim 1 or claim 2, wherein the mood disorder is depression.

4. The use of any one of claims 1 to 3, wherein the medicament is formulated for oral, subcutaneous, intravenous, or intramuscular administration.

5. The use of claim 4, wherein the medicament is formulated for oral administration.


6. The use according to any one of claims 1-5, wherein the mood disorder is postnatal depression.

7. Use of a pharmaceutically acceptable salt of a compound of the formula:



in the manufacture of a medicament for modulating a $GABA_A$ receptor in a human subject.

8. Use of a compound of the formula:



in the manufacture of a medicament for modulating a $GABA_A$ receptor in a human subject.

9. The use of claim 7 or claim 8, wherein the compound affects the $GABA_A$ receptor in a positive manner.


10. The use of any one of claims 7 to 9, wherein the subject has a mood disorder.

11. The use of claim 10, wherein the mood disorder is depression.

12. The use of any of claims 7 to 11, wherein the medicament is formulated for oral, subcutaneous, intravenous, or intramuscular administration.


13. The use of claim 12, wherein the medicament is formulated for oral administration.

14. Use of a pharmaceutically acceptable salt of a compound of the formula:



in the manufacture of a medicament for treating tremor in a human subject.

15. Use of a compound of the formula:



in the manufacture of a medicament for treating tremor in a human subject.

16. The use of claim 14 or claim 15, wherein the medicament is formulated for oral, subcutaneous, intravenous, or intramuscular administration.

17. The use of claim 16, wherein the medicament is formulated for oral administration.

18. The use according to claim 1 or claim 2, wherein the mood disorder is generalized anxiety disorder.

19. The use of claim 18, wherein the medicament is formulated for oral, subcutaneous, intravenous, or intramuscular administration.

20. The use of claim 19, wherein the medicament is formulated for oral administration.

21. The use according to claim 1 or claim 2, wherein the mood disorder is bipolar disorder.

22. The use of claim 21, wherein the bipolar disorder is bipolar I.

23. The use of claim 21, wherein the bipolar disorder is bipolar II.

24. The use of any one of claims 21-23, wherein the medicament is formulated for oral, subcutaneous, intravenous, or intramuscular administration.

25. The use of claim 24, wherein the medicament is formulated for oral administration.

26. The use according to any one of claims 1-5, wherein the mood disorder is major depressive disorder.